These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

690 related items for PubMed ID: 16782727

  • 1. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
    Eom KS, Min CK, Lee S, Kim YJ, Kim SY, Kim HJ, Lee JW, Min WS, Kim CC.
    Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727
    [Abstract] [Full Text] [Related]

  • 2. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH, Korean Multiple Myeloma Working Party.
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [Abstract] [Full Text] [Related]

  • 3. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, Olavarria E, Goldman JM, Rahemtulla A.
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [Abstract] [Full Text] [Related]

  • 4. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I, Vignetti M, Meloni G, Vegna ML, Scimè R, Tringali S, Amaddii G, Coser P, Tribalto M, Raimondi R, Bergonzi C, Sajeva MR, Sica S, Ferrando F, Messina G, Mandelli F.
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [Abstract] [Full Text] [Related]

  • 5. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S.
    Cancer; 2010 Jul 01; 116(13):3143-51. PubMed ID: 20564642
    [Abstract] [Full Text] [Related]

  • 6. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
    Wechalekar A, Amato D, Chen C, Keith Stewart A, Reece D.
    Ann Hematol; 2005 Feb 01; 84(2):115-7. PubMed ID: 15503021
    [Abstract] [Full Text] [Related]

  • 7. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW.
    Biol Blood Marrow Transplant; 2007 Aug 01; 13(8):925-31. PubMed ID: 17640596
    [Abstract] [Full Text] [Related]

  • 8. Effect of complete response on outcome following autologous stem cell transplantation for myeloma.
    Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA, Larson D, Therneau TM, Kyle RA, Litzow MR, Greipp PR, Gertz MA.
    Bone Marrow Transplant; 2000 Nov 01; 26(9):979-83. PubMed ID: 11100277
    [Abstract] [Full Text] [Related]

  • 9. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
    Cheema PK, Zadeh S, Kukreti V, Reece D, Chen C, Trudel S, Mikhael J.
    Biol Blood Marrow Transplant; 2009 Jun 01; 15(6):686-93. PubMed ID: 19450753
    [Abstract] [Full Text] [Related]

  • 10. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
    Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, Van Rhee F, Cottler-Fox M, Thertulien R, Muwalla F, Mazher S, Badros A, Tricot G.
    Bone Marrow Transplant; 2002 Dec 01; 30(12):873-8. PubMed ID: 12476279
    [Abstract] [Full Text] [Related]

  • 11. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
    Björkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, Marcus R, Boogaerts M, Alegre A, Remes K, Cornelissen JJ, Bladé J, Lenhoff S, Iriondo A, Carlson K, Volin L, Littlewood T, Goldstone AH, San Miguel J, Schattenberg A, Gahrton G.
    Bone Marrow Transplant; 2001 Mar 01; 27(5):511-5. PubMed ID: 11313685
    [Abstract] [Full Text] [Related]

  • 12. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma.
    Elice F, Raimondi R, Tosetto A, D'Emilio A, Di Bona E, Piccin A, Rodeghiero F.
    Am J Hematol; 2006 Jun 01; 81(6):426-31. PubMed ID: 16680735
    [Abstract] [Full Text] [Related]

  • 13. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
    Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E.
    Clin Transplant; 2009 Jun 01; 23(6):839-47. PubMed ID: 20447186
    [Abstract] [Full Text] [Related]

  • 14. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, Sharma A, Singh R, Kochupillai V.
    Natl Med J India; 2003 Jun 01; 16(1):16-21. PubMed ID: 12715951
    [Abstract] [Full Text] [Related]

  • 15. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.
    Jpn J Clin Oncol; 2009 Jul 01; 39(7):449-55. PubMed ID: 19487425
    [Abstract] [Full Text] [Related]

  • 16. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP.
    Biol Blood Marrow Transplant; 2008 Jan 01; 14(1):116-24. PubMed ID: 18158968
    [Abstract] [Full Text] [Related]

  • 17. Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: very long-term follow up of a single center experience.
    Kennedy GA, Butler J, Morton J, Hill G, Western R, Cummings J, Allison R, Durrant S.
    Clin Lab Haematol; 2006 Jun 01; 28(3):189-97. PubMed ID: 16706936
    [Abstract] [Full Text] [Related]

  • 18. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
    O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V, Naresh K, Lampert I, Samson D, Narat S, Kanfer E, Olavarria E, Apperley JF, Rahemtulla A.
    Bone Marrow Transplant; 2006 Apr 01; 37(8):731-7. PubMed ID: 16501593
    [Abstract] [Full Text] [Related]

  • 19. [Intensive treatment of multiple myeloma].
    Harousseau JL.
    Bull Acad Natl Med; 2003 Apr 01; 187(2):405-13; discussion 413-5. PubMed ID: 14556449
    [Abstract] [Full Text] [Related]

  • 20. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
    Cavo M, Di Raimondo F, Zamagni E, Patriarca F, Tacchetti P, Casulli AF, Volpe S, Perrone G, Ledda A, Ceccolini M, Califano C, Bigazzi C, Offidani M, Stefani P, Ballerini F, Fiacchini M, de Vivo A, Brioli A, Tosi P, Baccarani M.
    J Clin Oncol; 2009 Oct 20; 27(30):5001-7. PubMed ID: 19720903
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.